Functionally antagonistic roles of EZH2 and SWI/SNF have previously been demonstrated, leading to the hypothesis that targeting EZH2 in SWI/SNF mutant cancers could be effective due to synthetic lethality [75]. Here, SMARCA1 is linked to cancer.